References
- Giacomini KM , HuangSM, TweedieDJ et al. Membrane transporters in drug development: report from the FDA critical path initiative-sponsored workshop. Nat. Rev. Drug Discov. 9 , 215–236 (2010).
- Ramsey LB , BruunGH, YangW et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 22(1) , 1–8 (2012).
- Trevino LR , ShimasakiN, YangW et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27 , 5972–5978 (2009).
- Tirona RG , LeakeBF, MerinoNJ, KimRB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European– and African–Americans. J. Biol. Chem.276 , 35669–35675 (2001).
- Niemi M , BackmanJT, KajosaariLI et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77 , 468–478 (2005).
- Niemi M , KivistoH, HofmannU et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59 , 602–604 (2005).
- Nakagawa H , ToyodaY, Wakabayashi-NakaoK et al. Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts. J. Pharm. Sci. 100 , 3602–3619 (2011).
- Ishikawa T , Wakabayashi-NakaoK, NakagawaH. Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporters. Methods Mol. Biol. (2012) (In Press).
- Niemi M , PasanenMK, NeuvonenPJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev.63 , 157–181 (2011).
- Johnson AD , KavousiM, SmithAV et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18 , 2700–2710 (2009).
References
- Deahal SS , KupferD. CYP2D6 catalyzes tomoxifen 4-hydroxylation in human liver. Cancer Res.57 , 3402–3406 (1997).
- Kiyotani K , MushirodaT, NakamuraY, ZembutsuH. Pharmacogenomics of tamoxifen: role of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet.27 , 122–131 (2012).
- Kiyotani K , MushirodaT, ImamuraCK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28 , 1287–1293 (2010).
- Kiyotani K , MushirodaT, TsunodaT et al. A genome-wide association study identifies locus at 10.22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21 , 1665–1672 (2012).
- Lymberis SC , ParbarPK, KatsoulakisE, FormentiSC. Pharmacogenomics and breast cancer. Pharmacogenomics5 , 31–55 (2004).
- Early Breast Cancer Trialists‘ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365 , 1687–1717 (2005).
- Early Breast Cancer Trialists‘ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet351 , 1451–1467 (1998).